We regularly work with healthcare professionals (HCPs) and healthcare organizations (HCOs) who advise us on a range of topics such as medicines development, the role of a medicine in a patient treatment pathway, health economics and clinical best practice. These working relationships are essential to gaining the real-world information we need in order to deliver treatment choices that improve the health of patients and to share information that may be relevant to clinical decision making.
We want people to know, and understand, what we do and how we do it. We are committed to transparency about how we operate as a business and about the relationships we have with HCPs and HCOs. Sharing information about these relationships in a straightforward and open way will, we hope, help explain the critical value these relationships bring to patient management.
We believe that transparency is essential to building and maintaining confidence in us and in our medicines and strongly support the work being done by The European Federation of Pharmaceutical Industries and Associations (EFPIA) to improve transparency across the pharmaceutical industry.
The EFPIA Disclosure Code provides a common basis for reporting across Europe in relation to transfers of value. For more information on this Code visit: https://efpia.eu/.
The Cyprus Association of Research and Development Pharmaceutical Companies (KEFEA), a member of EFPIA, has adopted its own Disclosure Code that can be found here: http://kefea.org.cy/.
The publication of this information is made for transparency purposes only, as further detailed in the Pfizer EEA HCP Privacy Policy at https://privacycenter.pfizer.com/en/hcp-el (section “Disclosures of transfer of value”). It does not entail a general authorization to those accessing the website to carry out any further processing of health care professionals' (HCP’s) data, such as combining it with the information published on other websites.
Disclosure of payments made to HCPs and HCOs during each year, are available below: